<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Ceftriaxone" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Ceftriaxone</book-part-id>
      <title-group>
        <title>Ceftriaxone</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>20</day>
          <month>12</month>
          <year>2021</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Cedazuridine" document-type="chapter">Cedazuridine</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Celecoxib" document-type="chapter">Celecoxib</related-object>
    </book-part-meta>
    <body>
      <sec id="Ceftriaxone.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Ceftriaxone.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Ceftriaxone is a third generation cephalosporin antibiotic which has been associated with development of biliary sludge and biliary colic when given parenterally and in high doses. Ceftriaxone is also associated with rare instances of immunoallergic, usually cholestatic hepatitis similar to the injury associated with other cephalosporins.</p>
        </sec>
        <sec id="Ceftriaxone.Background">
          <title>Background</title>
          <p>Ceftriaxone (sef" trye ax' one) is a third generation cephalosporin was approved for use in the United States in 1984, and it continues to be widely used. Ceftriaxone is available in a parenteral formulation generically and under the brand name of Rocephin. It can be given either intravenously or intramuscularly and is indicated for therapy of moderate-to-severe bacterial infections caused by susceptible organisms. Typical dose regimens in adults are 1 to 2 grams given im or iv in one or two divided doses daily for 7 to 14 days. The parenteral cephalosporins are widely used in medicine for serious infections and can be safely given to patients with advanced liver disease, dose modifications being required mainly for renal insufficiency. Ceftriaxone is also approved for use in children. Ceftriaxone is generally well tolerated; adverse events can include diarrhea, nausea, abdominal pain, dyspepsia, headache, and rash. Rare but potentially severe adverse events include Clostridium difficile-associated diarrhea, hypersensitivity reactions, angioedema, anaphylaxis and Stevens Johnson syndrome/toxic epidermal necrolysis.</p>
        </sec>
        <sec id="Ceftriaxone.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>Parenteral administration of ceftriaxone has been associated with development of biliary sludge in 3% to 46% of patients. The incidence may be higher in children than adults and is associated with higher doses and longer courses of treatment and possibly with fasting or dehydration. The syndrome is referred to as &#x0201c;pseudolithiasis&#x0201d; as the sludge and stones consist largely of ceftriaxone and they resolve spontaneously when the drug is stopped, indicating that surgery can be avoided. Most cases occur with minimal or no symptoms. Frank symptoms of cholecystitis are reported in up to 5% of patients who develop pseudo-lithiasis. Typically, serum enzymes and bilirubin levels remain normal even with biliary colic, but in rare instances there is cholestatic jaundice or gallstone pancreatitis that can be severe and require surgical intervention. Sludge and symptoms of gallbladder disease can arise within a few days of starting therapy, but typically resolve rapidly once ceftriaxone is stopped, although sludge and gallstones may be detectable by ultrasound for several months.</p>
          <p>Ceftriaxone can also lead to an immunoallergic form of cholestatic hepatitis similar to what has been described with other cephalosporins. This reaction is idiosyncratic and is very rare. Symptoms of abdominal pain, nausea, pruritis and jaundice arise within 1 to 4 weeks of initiation of therapy and may worsen for 1 to 2 weeks after stopping the antibiotic. A cholestatic pattern of serum enzyme elevations and immunoallergic features of fever, rash and eosinophilia are common. The injury is usually mild and self-limited.</p>
          <p>Likelihood score: B (ceftriaxone is a very likely cause of clinically apparent liver injury and can also lead to biliary sludge and &#x0201c;pseudolithiasis&#x0201d; caused by crystallization of ceftriaxone in bile present in the gallbladder or biliary tree).</p>
        </sec>
        <sec id="Ceftriaxone.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>The mechanism of biliary sludge formation during ceftriaxone therapy appears to be the propensity of ceftriaxone to bind calcium and form insoluble crystals in bile in the gallbladder, resulting in biliary sludge or frank stones. This complication is not idiosyncratic, being demonstrable in animal models. In a similar manner, calcium salts of ceftriaxone can precipitate in urine and lead to sludge in ureters or bladder that are capable of causing urinary obstruction or symptomatic kidney and bladder stones. The rare, idiosyncratic acute cholestatic liver injury linked to ceftriaxone is probably due to hypersensitivity.</p>
        </sec>
        <sec id="Ceftriaxone.Outcome_and_Management">
          <title>Outcome and Management</title>
          <p>In most case reports, recovery has been rapid within 1 to 2 weeks, but some patients have required cholecystectomy during the acute illness and stones or sludge may persist for up to several months. The immunoallergic form of cholestatic hepatitis generally resolves rapidly and has not been associated with acute liver failure or chronic injury.</p>
          <p>Drug Class: Antiinfective Agents, <related-object link-type="booklink" source-id="livertox" document-id="Cephalosporins" document-type="chapter">Cephalosporins</related-object></p>
        </sec>
      </sec>
      <sec id="Ceftriaxone.CASE_REPORT">
        <title>CASE REPORT</title>
        <sec id="Ceftriaxone.Case_1_Biliary_sludge_and_ch">
          <title>Case 1. Biliary sludge and cholestatic hepatitis during intravenous administration of ceftriaxone.(<xref ref-type="bibr" rid="Ceftriaxone.REF.1">1</xref>)</title>
          <p>A 73 year old woman with rheumatoid arthritis developed nausea and right upper quadrant pain on the twelfth day of therapy with iv ceftriaxone for Klebsiella sepsis. A DISIDA scan demonstrated nonvisualization of the gallbladder and no excretion after 4 hours, suggesting common bile duct obstruction. Serum enzymes and amylase levels, which had been normal on admission, were increased. Abdominal ultrasound showed multiple small calculi in the gallbladder, but no biliary dilatation. Ultrasound done early during the hospitalization (for evaluation of renal disease) had shown a normal gallbladder without stones. Ceftriaxone was stopped a few days later and her abdominal pain and nausea improved promptly. Four days later, amylase and ALT levels were normal. Four weeks later, ultrasound demonstrated disappearance of the gallstones and alkaline phosphatase levels were normal.</p>
          <sec id="Ceftriaxone.Key_Points">
            <title>Key Points</title>
            <table-wrap id="Ceftriaxone.Tc" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <tbody>
                  <tr>
                    <th id="hd_b_Ceftriaxone.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Medication:</th>
                    <td headers="hd_b_Ceftriaxone.Tc_1_1_1_1" valign="top" align="left" rowspan="1" colspan="1">Ceftriaxone, 1.0 gram iv every 12 hours for 14 days</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Ceftriaxone.Tc_1_1_2_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pattern:</th>
                    <td headers="hd_b_Ceftriaxone.Tc_1_1_2_1" valign="top" align="left" rowspan="1" colspan="1">Cholestatic (R=1.7)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Ceftriaxone.Tc_1_1_3_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Severity:</th>
                    <td headers="hd_b_Ceftriaxone.Tc_1_1_3_1" valign="top" align="left" rowspan="1" colspan="1">1+ (no jaundice)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Ceftriaxone.Tc_1_1_4_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Latency:</th>
                    <td headers="hd_b_Ceftriaxone.Tc_1_1_4_1" valign="top" align="left" rowspan="1" colspan="1">12 days</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Ceftriaxone.Tc_1_1_5_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Recovery:</th>
                    <td headers="hd_b_Ceftriaxone.Tc_1_1_5_1" valign="top" align="left" rowspan="1" colspan="1">Complete in 4 weeks</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Ceftriaxone.Tc_1_1_6_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Other medications:</th>
                    <td headers="hd_b_Ceftriaxone.Tc_1_1_6_1" valign="top" align="left" rowspan="1" colspan="1">Piroxicam, ranitidine, furosemide, thyroxine, vitamin D, calcium</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </sec>
          <sec id="Ceftriaxone.Laboratory_Values">
            <title>Laboratory Values</title>
            <table-wrap id="Ceftriaxone.Td" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_Ceftriaxone.Td_1_1_1_1" valign="top" align="center" scope="col" rowspan="1" colspan="1">Time After<break/>Starting</th>
                    <th id="hd_h_Ceftriaxone.Td_1_1_1_2" valign="top" align="center" scope="col" rowspan="1" colspan="1">Time After<break/>Stopping</th>
                    <th id="hd_h_Ceftriaxone.Td_1_1_1_3" valign="top" align="center" scope="col" rowspan="1" colspan="1">ALT<break/>(U/L)</th>
                    <th id="hd_h_Ceftriaxone.Td_1_1_1_4" valign="top" align="center" scope="col" rowspan="1" colspan="1">Alk P<break/>(U/L)</th>
                    <th id="hd_h_Ceftriaxone.Td_1_1_1_5" valign="top" align="center" scope="col" rowspan="1" colspan="1">Bilirubin<break/>(mg/dL)</th>
                    <th id="hd_h_Ceftriaxone.Td_1_1_1_6" valign="top" align="center" scope="col" rowspan="1" colspan="1">Other</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pre</td>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">51</td>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">103</td>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">0.2</td>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Admission for GI bleeding</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">0</td>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_3 hd_h_Ceftriaxone.Td_1_1_1_4 hd_h_Ceftriaxone.Td_1_1_1_5 hd_h_Ceftriaxone.Td_1_1_1_6" colspan="4" valign="top" align="center" rowspan="1">Ceftriaxone started (day 7 of hospitalization)</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">12 days</td>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_3 hd_h_Ceftriaxone.Td_1_1_1_4 hd_h_Ceftriaxone.Td_1_1_1_5 hd_h_Ceftriaxone.Td_1_1_1_6" colspan="4" valign="top" align="center" rowspan="1">Abdominal pain and nausea: gallbladder sludge</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">13 days</td>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">92</td>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">183</td>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">0.4</td>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Amylase 513</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">14 days</td>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">252</td>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">299</td>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">Normal</td>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Ceftriaxone stopped</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">18 days</td>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">4 days</td>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">52</td>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">245</td>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_5" valign="top" align="left" rowspan="1" colspan="1"/>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Ultrasound: single gallstone</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">6 weeks</td>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">4 weeks</td>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">Normal</td>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">Normal</td>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">Normal</td>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1">Ultrasound: no gallstones</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_1 hd_h_Ceftriaxone.Td_1_1_1_2" colspan="2" valign="top" align="center" scope="row" rowspan="1">
<bold>Normal Values</bold>
</td>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_3 hd_h_Ceftriaxone.Td_1_1_1_4" colspan="2" valign="top" align="center" rowspan="1">
<bold>Not given</bold>
</td>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;1.2</bold>
</td>
                    <td headers="hd_h_Ceftriaxone.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </sec>
          <sec id="Ceftriaxone.Comment">
            <title>Comment</title>
            <p>Only 5% to 10% of patients who develop biliary sludge (pseudolithiasis) during ceftriaxone therapy develop symptoms of biliary colic and, even with symptoms, patients rarely develop elevations of serum enzymes or bilirubin levels. The case described above developed what appeared to be a gallstone pancreatitis and partial biliary obstruction leading to mild elevations in serum aminotransferase and alkaline phosphatase levels, but without jaundice. The development of ceftriaxone biliary stones during therapy and dissolution afterwards was nicely documented in this case report. The biliary symptoms resolved with a day or two and the stones within 4 weeks of stopping therapy.</p>
          </sec>
        </sec>
      </sec>
      <sec id="Ceftriaxone.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
<bold>REPRESENTATIVE TRADE NAMES</bold>
</p>
        <p>Ceftriaxone &#x02013; Generic, Rocephin&#x000ae;</p>
        <p>
<bold>DRUG CLASS</bold>
</p>
        <p>Antiinfective Agents</p>
        <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=Ceftriaxone">COMPLETE LABELING</ext-link>
</p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Ceftriaxone.CHEMICAL_FORMULA_AND_STRUCTU">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Ceftriaxone.Te" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Ceftriaxone.Te_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Ceftriaxone.Te_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">CAS REGISTRY NO</th>
                <th id="hd_h_Ceftriaxone.Te_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Ceftriaxone.Te_1_1_1_4" valign="top" align="left" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Ceftriaxone.Te_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Ceftriaxone Sodium</td>
                <td headers="hd_h_Ceftriaxone.Te_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://135010859">74578-69-1</ext-link>
</td>
                <td headers="hd_h_Ceftriaxone.Te_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C18-H18-N8-O7-S3.2Na</td>
                <td headers="hd_h_Ceftriaxone.Te_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
<related-object link-type="ext-image-back-link" source-id="pubchem" document-id="135010859" document-id-type="sid" document-type="summary" object-id="135010859" object-id-type="sid" object-type="image"/>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Ceftriaxone.CITED_REFERENCES">
        <title>CITED REFERENCES</title>
        <ref-list id="Ceftriaxone.CITED_REFERENCES.reflist0">
          <ref id="Ceftriaxone.REF.1">
            <label>1</label>
            <element-citation publication-type="journal">
              <person-group>
<collab>Modified from</collab>
</person-group>
              <article-title>Zinberg J, Chernaik R, Coman E, Rosenblatt R, Brandt LJ. Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis.</article-title>
              <source>Am J Gastroenterol.</source>
              <year>1991</year>
              <volume>86</volume>
              <issue>9</issue>
              <fpage>1251</fpage>
              <lpage>4</lpage>
              <pub-id pub-id-type="pmid">1882806</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec id="Ceftriaxone.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 20 December 2021</p>
        <ref-list id="Ceftriaxone.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Ceftriaxone.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Cephalosporins. In, Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd Ed. Philadelphia: Lippincott, 1999. p. 589-92.<annotation><p><italic toggle="yes">(Expert review of cephalosporins and liver injury published in 1999).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Ceftriaxone.REF.moseley.2013">
            <mixed-citation publication-type="book">Moseley RH. Hepatotoxicity of antimicrobials and antifungal agents. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013. p. 463-83.<annotation><p><italic toggle="yes">(Review of cephalosporin induced liver injury mentions that ceftriaxone has been linked to biliary sludge and concretions and with occasional reports of cholestatic hepatitis).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Ceftriaxone.REF.petri.2011">
            <mixed-citation publication-type="book">Petri WA Jr. Penicillins, cephalosporins, and other &#x000df;-lactam antibiotics. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman's The pharmacological basis of therapeutics, 12th ed. New York: McGraw-Hill, 2011: 1477-1504.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Ceftriaxone.REF.file.1984.653">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>File</surname><given-names>TM</given-names><suffix>Jr</suffix></name>
<name name-style="western"><surname>Tan</surname><given-names>JS</given-names></name>
<name name-style="western"><surname>Salstrom</surname><given-names>SJ</given-names></name>
</person-group>
              <article-title>Clinical evaluation of ceftriaxone.</article-title>
              <source>Clin Ther</source>
              <year>1984</year>
              <volume>6</volume>
              <fpage>653</fpage>
              <lpage>61</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Analysis of 77 patients receiving ceftriaxone for serious infections; 93% efficacy; ALT elevations in 8 [10%, peak levels 92 U/L] ).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">6090021</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.oakes.1984.89">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Oakes</surname><given-names>M</given-names></name>
<name name-style="western"><surname>MacDonald</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Wilson</surname><given-names>D</given-names></name>
</person-group>
              <article-title>Abnormal laboratory test values during ceftriaxone therapy.</article-title>
              <source>Am J Med</source>
              <year>1984</year>
              <volume>77</volume>
              <fpage>89</fpage>
              <lpage>96</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Analysis of laboratory test abnormalities among 2640 patients receiving ceftriaxone for 1 day to 6 weeks at varying doses in prelicensure studies; ALT elevations occurred in 3.1%, Alk P 1.0% and bilirubin in 0.3%; rates that were similar to those of other iv cephalosporins; one case had ALT elevations with jaundice which resolved ultimately, but was not otherwise characterized).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">6093527</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.moskovitz.1984.84">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Moskovitz</surname><given-names>BL</given-names></name>
</person-group>
              <article-title>Clinical adverse effects during ceftriaxone therapy.</article-title>
              <source>Am J Med</source>
              <year>1984</year>
              <volume>77</volume>
              <issue>4C</issue>
              <fpage>84</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Review of adverse effects of ceftriaxone in prelicensure studies; 2640 patients in 153 studies, allergic reactions in 3%; jaundice in 2 patients, both of whom were septic and resolved with stopping therapy; no mention of biliary cholic).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">6093526</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.parry.1984.358">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Parry</surname><given-names>MF</given-names></name>
</person-group>
              <article-title>Toxic and adverse reactions encountered with new beta-lactam antibiotics.</article-title>
              <source>Bull N Y Acad Med</source>
              <year>1984</year>
              <volume>60</volume>
              <fpage>358</fpage>
              <lpage>68</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Review suggesting that hepatitis occurs in "2-5%" of cephalosporin- and penicillin treated patients).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">6586251</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.barson.1985.362">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Barson</surname><given-names>WJ</given-names></name>
<name name-style="western"><surname>Miller</surname><given-names>MA</given-names></name>
<name name-style="western"><surname>Brady</surname><given-names>MT</given-names></name>
<name name-style="western"><surname>Powell</surname><given-names>DA</given-names></name>
</person-group>
              <article-title>Prospective comparative trial of ceftriaxone vs. conventional therapy for treatment of bacterial meningitis in children.</article-title>
              <source>Pediatr Infect Dis</source>
              <year>1985</year>
              <volume>4</volume>
              <fpage>362</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Trial comparing ceftriaxone to ampicillin with chloramphenicol for meningitis in 50 children; similar efficacy, more diarrhea with ceftriaxone and 11% had minor ALT elevations, returning to normal during or after therapy).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">3895175</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.schaad.1986.708">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Schaad</surname><given-names>UB</given-names></name>
<name name-style="western"><surname>Tsch&#x000e4;ppeler</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Lentze</surname><given-names>MJ</given-names></name>
</person-group>
              <article-title>Transient formation of precipitations in the gallbladder associated with ceftriaxone therapy.</article-title>
              <source>Pediatr Infect Dis</source>
              <year>1986</year>
              <volume>5</volume>
              <fpage>708</fpage>
              <lpage>10</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Initial report of transient biliary sludge in a 18 year old male with chronic granulomatous disease receiving iv ceftriaxone, who was found to have gallbladder abnormalities incidentally while being followed for a splenic abscess with repeat ultrasound examinations; the stones appeared during therapy and resolved soon after ceftriaxone was stopped).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">3540889</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.norrby.1987.105">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Norrby</surname><given-names>SR</given-names></name>
</person-group>
              <article-title>Side effects of cephalosporins.</article-title>
              <source>Drugs</source>
              <year>1987</year>
              <volume>34</volume>
              <supplement>Suppl 2</supplement>
              <fpage>105</fpage>
              <lpage>20</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Clinical review of cephalosporins: ALT elevations occur in 1-8% of treated patients, but clinically apparent hepatitis is rare, usually occurring with allergic symptoms; little evidence for cross hypersensitivity with penicillins).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">3319495</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.schaad.1988.1411">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Schaad</surname><given-names>UB</given-names></name>
<name name-style="western"><surname>Wedgwood-Krucko</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Tsch&#x000e4;ppeler</surname><given-names>H</given-names></name>
</person-group>
              <article-title>Reversible ceftriaxone-associated biliary pseudolithiasis in children.</article-title>
              <source>Lancet</source>
              <year>1988</year>
              <volume>2</volume>
              <fpage>1411</fpage>
              <lpage>3</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Prospective ultrasound study of 37 children receiving ceftriaxone; 16 [43%] developed sludge and 1 urolithiasis in 4 to 22 days, 3 [8%] symptomatic, all resolved in 2-63 days; referred to syndrome as "biliary pseudolithiasis").</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">2904533</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.jacobs.1988.434">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Jacobs</surname><given-names>RF</given-names></name>
</person-group>
              <article-title>Ceftriaxone-associated cholecystitis.</article-title>
              <source>Pediatr Infect Dis J</source>
              <year>1988</year>
              <volume>7</volume>
              <fpage>434</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
<italic toggle="yes">(16 year old girl given 2 g ceftriaxone iv twice daily, and 3 days later developed biliary colic with raised GGT [184 U/L], resolved in 8 weeks).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">3293002</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.meyboom.1988.858">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Meyboom</surname><given-names>RH</given-names></name>
<name name-style="western"><surname>Kuiper</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Jansen</surname><given-names>A</given-names></name>
</person-group>
              <article-title>Ceftriaxone and reversible cholelithiasis.</article-title>
              <source>BMJ</source>
              <year>1988</year>
              <volume>297</volume>
              <fpage>858</fpage>
              <annotation>
                <p>
<italic toggle="yes">(Two cases of biliary colic in adults during ceftriaxone therapy, both resolved; cholecystectomy later in one showed no stones and no abnormalities of gallbladder).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">3140956</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.pigrau.1989.165">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Pigrau</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Pahissa</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Gropper</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Sureda</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Martinez Vazquez</surname><given-names>JM</given-names></name>
</person-group>
              <article-title>Ceftriaxone-associated biliary pseudolithiasis in adults.</article-title>
              <source>Lancet</source>
              <year>1989</year>
              <volume>2</volume>
              <fpage>165</fpage>
              <annotation>
                <p>
<italic toggle="yes">(Prospective ultrasound study in 20 adults receiving iv ceftriaxone; 5 [25%] developed stones by 4-17 days, all resolving in 7-26 days, serum enzymes normal and no symptoms; stones correlated with total ceftriaxone dose [5-80 g]).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">2567936</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.cometta.1990.689">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Cometta</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Gallot-Lavall&#x000e9;e-Villars</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Iten</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Cantoni</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Anderegg</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Convers</surname><given-names>JJ</given-names></name>
<name name-style="western"><surname>Glauser</surname><given-names>MP</given-names></name>
</person-group>
              <article-title>Incidence of gallbladder lithiasis after ceftriaxone treatment.</article-title>
              <source>J Antimicrob Chemother</source>
              <year>1990</year>
              <volume>25</volume>
              <fpage>689</fpage>
              <lpage>95</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Prospective study of 34 patients given amoxicillin/clavulanate vs 40 given ceftriaxone; follow up 6 and 12 months later showed only one gallstone - in an amoxicillin/clavulanate treated patient; ultrasound not done during therapy).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">2190975</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.heimduthoy.1990.1146">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Heim-Duthoy</surname><given-names>KL</given-names></name>
<name name-style="western"><surname>Caperton</surname><given-names>EM</given-names></name>
<name name-style="western"><surname>Pollock</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Matzke</surname><given-names>GR</given-names></name>
<name name-style="western"><surname>Enthoven</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Peterson</surname><given-names>PK</given-names></name>
</person-group>
              <article-title>Apparent biliary pseudolithiasis during ceftriaxone therapy.</article-title>
              <source>Antimicrob Agents Chemother</source>
              <year>1990</year>
              <volume>34</volume>
              <fpage>1146</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Prospective study in 28 adults on iv ceftriaxone and 8 controls for 14 days found abnormalities in 6 [21%] treated and 1 [12%] controls after 14 days; 2 were symptomatic, all resolved spontaneously within 9 to 26 days).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">2203305</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.shiffman.1990.1772">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Shiffman</surname><given-names>ML</given-names></name>
<name name-style="western"><surname>Keith</surname><given-names>FB</given-names></name>
<name name-style="western"><surname>Moore</surname><given-names>EW</given-names></name>
</person-group>
              <article-title>Pathogenesis of ceftriaxone-associated biliary sludge. In vitro studies of calcium-ceftriaxone binding and solubility.</article-title>
              <source>Gastroenterology</source>
              <year>1990</year>
              <volume>99</volume>
              <fpage>1772</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Ceftriaxone binds calcium in vitro and forms precipitations when added at high concentrations to human bile).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">2227290</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.schaad.1990.141">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Schaad</surname><given-names>UB</given-names></name>
<name name-style="western"><surname>Suter</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Gianella-Borradori</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Pfenninger</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Auckenthaler</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Bernath</surname><given-names>O</given-names></name>
<name name-style="western"><surname>Cheseaux</surname><given-names>JJ</given-names></name>
<etal/>
</person-group>
              <article-title>A comparison of ceftriaxone and cefuroxime for treatment of bacterial meningitis in children.</article-title>
              <source>N Engl J Med</source>
              <year>1990</year>
              <volume>322</volume>
              <fpage>141</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Prospective study comparing ceftriaxone and cefuroxime in 106 children with meningitis; all were cured; ultrasound identified sludge in 16 of 35 treated with ceftriaxone, but none in 35 cefuroxime treated children after 3-10 days; sludge resolved completely in 11 to 63 days after therapy; 3 [9%] had colic).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">2403654</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.fekety.1990.38s">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Fekety</surname><given-names>FR</given-names></name>
</person-group>
              <article-title>Safety of parenteral third-generation cephalosporins.</article-title>
              <source>Am J Med</source>
              <year>1990</year>
              <volume>88</volume>
              <supplement>Suppl 4A</supplement>
              <fpage>38S</fpage>
              <lpage>44S</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Review article stating that aminotransferase elevations can occur on cephalosporin therapy, but clinically apparent liver disease is rare).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">2183609</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.lopez.1991.712">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Lopez</surname><given-names>AJ</given-names></name>
<name name-style="western"><surname>O'Keefe</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Morrissey</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Pickleman</surname><given-names>J</given-names></name>
</person-group>
              <article-title>Ceftriaxone-induced cholelithiasis.</article-title>
              <source>Ann Intern Med</source>
              <year>1991</year>
              <volume>115</volume>
              <fpage>712</fpage>
              <lpage>14</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Patient on iv ceftriaxone for endocarditis for unclear period of time developed pancreatitis and later underwent cholecystectomy demonstrating five soft, green ceftriaxone stones).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">1929040</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.zinberg.1991.1251">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Zinberg</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Chernaik</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Coman</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Rosenblatt</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Brandt</surname><given-names>LJ</given-names></name>
</person-group>
              <article-title>Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis.</article-title>
              <source>Am J Gastroenterol</source>
              <year>1991</year>
              <volume>86</volume>
              <fpage>1251</fpage>
              <lpage>4</lpage>
              <annotation>
                <p>
<italic toggle="yes">(73 year old woman with multiple medical problems developed biliary colic and pancreatitis [peak amylase 513 U/L] after 12 days of iv ceftriaxone for Klebsiella sepsis, with mild elevations in Alk P [299 U/L] and ALT [252 U/L], but no jaundice, resolving once ceftriaxone was stopped: Case 1).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">1882806</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.park.1991.1665">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Park</surname><given-names>HZ</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>SP</given-names></name>
<name name-style="western"><surname>Schy</surname><given-names>AL</given-names></name>
</person-group>
              <article-title>Ceftriaxone-associated gallbladder sludge. Identification of calcium-ceftriaxone salt as a major component of gallbladder precipitate.</article-title>
              <source>Gastroenterology</source>
              <year>1991</year>
              <volume>100</volume>
              <fpage>1665</fpage>
              <lpage>70</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Surgical specimens from 4 patients with biliary sludge after ceftriaxone therapy showed no stones, but rather granular-crystalline material of cholesterol [2%], bilirubin [14%] and calcium-ceftriaxone).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">2019372</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.kim.1992.618">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Kim</surname><given-names>YS</given-names></name>
<name name-style="western"><surname>Kestell</surname><given-names>MR</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>SP</given-names></name>
</person-group>
              <article-title>Gall-bladder sludge: lessons from ceftriaxone.</article-title>
              <source>J Gastroenterol Hepatol</source>
              <year>1992</year>
              <volume>7</volume>
              <fpage>618</fpage>
              <lpage>21</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Review and discussion of pathogenesis of ceftriaxone associated biliary sludge and stone formation).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">1486190</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.riccabona.1993.421">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Riccabona</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Kerbl</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Schwinger</surname><given-names>W</given-names></name>
<name name-style="western"><surname>Spork</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Millner</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Grubbauer</surname><given-names>HM</given-names></name>
</person-group>
              <comment>[Ceftriaxone-induced cholestasis - a harmless side-effect?]</comment>
              <source>Klin Padiatr</source>
              <year>1993</year>
              <volume>205</volume>
              <fpage>421</fpage>
              <lpage>3</lpage>
              <comment>German.</comment>
              <annotation>
                <p>
<italic toggle="yes">(Among 43 children receiving iv ceftriaxone, 20 developed sludge by ultrasound within 10 days, 2 developing serum enzyme abnormalities, another 3 had severe pain, but all resolved within 2 months).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">8309205</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.kirejczyk.1992.329">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Kirejczyk</surname><given-names>WM</given-names></name>
<name name-style="western"><surname>Crowe</surname><given-names>HM</given-names></name>
<name name-style="western"><surname>Mackay</surname><given-names>IM</given-names></name>
<name name-style="western"><surname>Quintiliani</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Cronin</surname><given-names>EB</given-names></name>
</person-group>
              <article-title>Disappearing &#x0201c;gallstones&#x0201d;: biliary pseudolithiasis complicating ceftriaxone therapy.</article-title>
              <source>AJR Am J Roentgenol</source>
              <year>1992</year>
              <volume>159</volume>
              <fpage>329</fpage>
              <lpage>30</lpage>
              <annotation>
                <p>
<italic toggle="yes">(19 year old woman with Lyme disease developed biliary colic 1 week after starting a 14 day course of iv ceftriaxone; had symptoms of fever and colic with gallstones on ultrasound that resolved in the next 3 weeks without therapy).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">1632349</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.michielsen.1992.32">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Michielsen</surname><given-names>PP</given-names></name>
<name name-style="western"><surname>Fierens</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Van Maercke</surname><given-names>YM</given-names></name>
</person-group>
              <article-title>Drug-induced gallbladder disease. Incidence, aetiology and management.</article-title>
              <source>Drug Saf</source>
              <year>1992</year>
              <volume>7</volume>
              <fpage>32</fpage>
              <lpage>45</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Review article on drug induced gallbladder disease focusing upon estrogens, clofibrate, ceftriaxone, octreotide, and hepatic artery chemotherapy).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">1536697</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.thompson.1993.132">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Thompson</surname><given-names>JW</given-names></name>
<name name-style="western"><surname>Jacobs</surname><given-names>RF</given-names></name>
</person-group>
              <article-title>Adverse effects of newer cephalosporins. An update.</article-title>
              <source>Drug Saf</source>
              <year>1993</year>
              <volume>9</volume>
              <fpage>132</fpage>
              <lpage>142</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Extensive review; transient increases in ALT, AST or Alk P have been reported in 0.7%, 6%, 11% and 28% of prospectively followed patients treated with various cephalosporins; clinically significant biliary sludging with ceftriaxone, particularly in children, not found with other cephalosporins).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">8397890</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.blais.1994.218">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Blais</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Duperval</surname><given-names>R</given-names></name>
</person-group>
              <article-title>Biliary pseudolithiasis in a child associated with 2 days of ceftriaxone therapy.</article-title>
              <source>Pediatr Radiol</source>
              <year>1994</year>
              <volume>24</volume>
              <fpage>218</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
<italic toggle="yes">(18 month old boy given iv ceftriaxone for 2 days, developed biliary colic on day 5, normal gallbladder and no stones found on cholecystectomy on day 11).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">7936805</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.barzilai.1994.163">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Barzilai</surname><given-names>M.</given-names></name>
</person-group>
              <comment>[Sonographic demonstration of pseudo-cholelithiasis after ceftriaxone]</comment>
              <source>Harefuah</source>
              <year>1994</year>
              <volume>127</volume>
              <fpage>163</fpage>
              <lpage>5</lpage>
              <comment>Hebrew.</comment>
              <annotation>
                <p>
<italic toggle="yes">(Case series of 2 children who developed symptoms and gallbladder sludge on ceftriaxone therapy; resolved with discontinuation).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">7995584</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.di_martino.1994.839">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Di Martino</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Cadranel</surname><given-names>JF</given-names></name>
<name name-style="western"><surname>Attali</surname><given-names>P</given-names></name>
</person-group>
              <comment>[Hepatobiliary complications induced by cephalosporins]</comment>
              <source>Gastroenterol Clin Biol</source>
              <year>1994</year>
              <volume>18</volume>
              <fpage>839</fpage>
              <lpage>46</lpage>
              <comment>French.</comment>
              <annotation>
                <p>
<italic toggle="yes">(Review of hepatobiliary complications of cephalosporins mentioning rare case reports of hepatotoxicity and issue of pseudolithiasis with ceftriaxone).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">7875391</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.ettestad.1995.356">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Ettestad</surname><given-names>PJ</given-names></name>
<name name-style="western"><surname>Campbell</surname><given-names>GL</given-names></name>
<name name-style="western"><surname>Welbel</surname><given-names>SF</given-names></name>
<etal/>
</person-group>
              <article-title>Biliary complications in the treatment of unsubstantiated Lyme disease.</article-title>
              <source>J Infect Dis</source>
              <year>1995</year>
              <volume>171</volume>
              <fpage>356</fpage>
              <lpage>61</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Case control study in a hospital that reported 1730 admissions for therapy of Lyme disease; among 1352 patients, 24 developed gallstone disease and 14 had cholecystectomy; all had received iv ceftriaxone).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">7844372</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.stabile.1995.590">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Stabile</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Ferrara</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Marietti</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Maresca</surname><given-names>G</given-names></name>
</person-group>
              <article-title>Ceftriaxone-associated gallbladder lithiasis in children.</article-title>
              <source>Eur J Pediatr</source>
              <year>1995</year>
              <volume>154</volume>
              <fpage>590</fpage>
              <annotation>
                <p>
<italic toggle="yes">(Prospective study of 41 children receiving iv ceftriaxone; 5 [12%] developed stones/sludge, one with symptoms, all resolved in 10-30 days).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">7556332</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.benedetti.1995.369">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Benedetti</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Zanchetta</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Bagnani</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Praderio</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Perbellini</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Melo</surname><given-names>C.</given-names></name>
</person-group>
              <comment>[Pseudolithiasis caused by ceftriaxone in children: a case report]</comment>
              <source>Pediatr Med Chir</source>
              <year>1995</year>
              <volume>17</volume>
              <fpage>369</fpage>
              <lpage>71</lpage>
              <comment>Italian.</comment>
              <annotation>
                <p>
<italic toggle="yes">(1 year old child developed symptomatic pseudolithiasis during iv ceftriaxone therapy, which resolved within 4 weeks of stopping).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">7491336</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.george.1996.79">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>George</surname><given-names>DK</given-names></name>
<name name-style="western"><surname>Crawford</surname><given-names>DH</given-names></name>
</person-group>
              <article-title>Antibacterial-induced hepatotoxicity. Incidence, prevention and management.</article-title>
              <source>Drug Saf</source>
              <year>1996</year>
              <volume>15</volume>
              <fpage>79</fpage>
              <lpage>85</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Review of hepatotoxicity from antibiotics with one sentence on cephalosporins, describing liver injury from this class as being extremely rare, although elevations in aminotransferases occurred in 0.7-11% of treated patients).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">8862966</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.robertson.1996.133">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Robertson</surname><given-names>FM</given-names></name>
<name name-style="western"><surname>Crombleholme</surname><given-names>TM</given-names></name>
<name name-style="western"><surname>Barlow</surname><given-names>SE</given-names></name>
<name name-style="western"><surname>Verhave</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Brown</surname><given-names>D</given-names></name>
</person-group>
              <article-title>Ceftriaxone choledocholithiasis.</article-title>
              <source>Pediatrics</source>
              <year>1996</year>
              <volume>98</volume>
              <fpage>133</fpage>
              <lpage>5</lpage>
              <annotation>
                <p>
<italic toggle="yes">(9 year old boy given 7 day course of iv ceftriaxone, developed biliary colic 5 days later, abnormal Alk P [335 U/L] and biliary dilatation on ultrasound; surgery found ceftriaxone stone in common bile duct).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">8668387</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.kong.1996.50">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Kong</surname><given-names>MS</given-names></name>
<name name-style="western"><surname>Chen</surname><given-names>CY</given-names></name>
</person-group>
              <article-title>Risk factors leading to ceftriaxone-associated biliary pseudolithiasis in children.</article-title>
              <source>Changgeng Yi Xue Za Zhi.</source>
              <year>1996</year>
              <volume>19</volume>
              <fpage>50</fpage>
              <lpage>4</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Prospective ultrasound study in 151 children receiving iv ceftriaxone; 5 [3%] developed asymptomatic pseudolithiasis after 3-7 days; risk factors were fasting and older age).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">8935375</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.longo.1998.836">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Longo</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Hastier</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Buckley</surname><given-names>MJ</given-names></name>
<name name-style="western"><surname>Chichmanian</surname><given-names>RM</given-names></name>
<name name-style="western"><surname>Delmont</surname><given-names>JP</given-names></name>
</person-group>
              <article-title>Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone.</article-title>
              <source>Am J Gastroenterol</source>
              <year>1998</year>
              <volume>93</volume>
              <fpage>836</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Elderly man developed jaundice with mixed enzyme elevations 3 days after a 12 day course of oral ceftriaxone; bilirubin 22 times, ALT 11 times and Alk P 6 times ULN, later developed severe hemolytic anemia requiring prednisone and resolving only by six months).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">9625142</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.maranan.1998.662">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Maranan</surname><given-names>MC</given-names></name>
<name name-style="western"><surname>Gerber</surname><given-names>SI</given-names></name>
<name name-style="western"><surname>Miller</surname><given-names>GG</given-names></name>
</person-group>
              <article-title>Gallstone pancreatitis caused by ceftriaxone.</article-title>
              <source>Pediatr Infect Dis J</source>
              <year>1998</year>
              <volume>17</volume>
              <fpage>662</fpage>
              <lpage>3</lpage>
              <annotation>
                <p>
<italic toggle="yes">(13 year old developed pancreatitis 4 days after stopping 5 weeks of ceftriaxone with several other antibiotics; amylase 1133 U/L but normal ALT. Cholecystectomy showed stones and chronic cholecystitis; analysis of stone showed "100%"ceftriaxone).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">9686742</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.herek.1999.337">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Herek</surname><given-names>O</given-names></name>
<name name-style="western"><surname>Sario&#x0011f;lu</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Ko&#x000e7;er</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Tiryaki</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Akkemik</surname><given-names>B</given-names></name>
</person-group>
              <article-title>Biliary pseudolithiasis in childhood: a case report.</article-title>
              <source>Eur J Pediatr Surg</source>
              <year>1999</year>
              <volume>9</volume>
              <fpage>337</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Case report of symptomatic biliary sludge arising after 6 days of intravenous ceftriaxone, resolving within 11 days of stopping).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">10584197</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.vega.1999.432">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Vega</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Quinby</surname><given-names>PM</given-names></name>
<name name-style="western"><surname>Aspy</surname><given-names>CB</given-names></name>
</person-group>
              <article-title>Hepato-biliary abnormalities secondary to ceftriaxone use: a case report.</article-title>
              <source>J Okla State Med Assoc</source>
              <year>1999</year>
              <volume>92</volume>
              <fpage>432</fpage>
              <lpage>4</lpage>
              <annotation>
                <p>
<italic toggle="yes">(10 month old with rotavirus infection given ceftriaxone developed elevated Alk P [3580 U/L] and AST [84 U/L] after ~7 days, normal gallbladder ultrasound, rapid recovery).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">10461415</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.papadopoulou.1999.1352">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Papadopoulou</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Efremidis</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Karyda</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Badouraki</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Karatza</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Panteliadis</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Malaka</surname><given-names>K</given-names></name>
</person-group>
              <article-title>Incidence of ceftriaxone-associated gallbladder pseudolithiasis.</article-title>
              <source>Acta Paediatr.</source>
              <year>1999</year>
              <volume>88</volume>
              <issue>12</issue>
              <fpage>1352</fpage>
              <lpage>5</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Prospective study in 44 children given iv ceftriaxone for 3 to 14 days; 11 [25%] developed pseudolithiasis after 2-9 days, 2 with symptoms [5%]; all resolved completely in 8-23 days).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">10626521</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.de_moor.1999.975">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>de Moor</surname><given-names>RA</given-names></name>
<name name-style="western"><surname>Egberts</surname><given-names>AC</given-names></name>
<name name-style="western"><surname>Schr&#x000f6;der</surname><given-names>CH</given-names></name>
</person-group>
              <article-title>Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis.</article-title>
              <source>Eur J Pediatr</source>
              <year>1999</year>
              <volume>158</volume>
              <fpage>975</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
<italic toggle="yes">(7 year old boy developed urinary stone and biliary sludge after 4 days of high dose iv ceftriaxone and passed a ceftriaxone containing urinary stone after 10 days).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">10592073</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.bonnet.2000.368">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Bonnet</surname><given-names>JP</given-names></name>
<name name-style="western"><surname>Abid</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Dabhar</surname><given-names>A</given-names></name>
<name name-style="western"><surname>L&#x000e9;vy</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Soulier</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Blangy</surname><given-names>S</given-names></name>
</person-group>
              <article-title>Early biliary pseudolithiasis during ceftriaxone therapy for acute pyelonephritis in children: a prospective study in 34 children.</article-title>
              <source>Eur J Pediatr Surg</source>
              <year>2000</year>
              <volume>10</volume>
              <fpage>368</fpage>
              <lpage>71</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Prospective study in 34 children given iv ceftriaxone with ultrasound before and at end of therapy; 5 [15%] developed asymptomatic gallstones, all resolved within 5 months).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">11215777</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.tuckuviene.2000.4271">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Tuckuviene</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Myrtue</surname><given-names>GS</given-names></name>
</person-group>
              <comment>[Symptomatic pseudolithiasis caused by Rocephalin]</comment>
              <source>Ugeskr Laeger</source>
              <year>2000</year>
              <volume>162</volume>
              <fpage>4271</fpage>
              <lpage>2</lpage>
              <comment>Danish.</comment>
              <annotation>
                <p>
<italic toggle="yes">(5 year old girl developed symptomatic pseudolithiasis on ceftriaxone, resolving rapidly with stopping).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">10962947</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.palanduz.2000.166">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Palanduz</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Yal&#x000e7;in</surname><given-names>I</given-names></name>
<name name-style="western"><surname>Tongu&#x000e7;</surname><given-names>E</given-names></name>
<name name-style="western"><surname>G&#x000fc;ler</surname><given-names>N</given-names></name>
<name name-style="western"><surname>One&#x0015f;</surname><given-names>U</given-names></name>
<name name-style="western"><surname>Salman</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Somer</surname><given-names>A</given-names></name>
</person-group>
              <article-title>Sonographic assessment of ceftriaxone-associated biliary pseudolithiasis in children.</article-title>
              <source>J Clin Ultrasound</source>
              <year>2000</year>
              <volume>28</volume>
              <fpage>166</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Prospective study of 118 children receiving 1-3 weeks of iv ceftriaxone found 17% developed sludge; all were asymptomatic and all resolved in 2 weeks; no risk factors observed).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">10751736</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.grasberger.2000.1076">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Grasberger</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Otto</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Loeschke</surname><given-names>K.</given-names></name>
</person-group>
              <article-title>Ceftriaxone-associated nephrolithiasis.</article-title>
              <source>Ann Pharmacother</source>
              <year>2000</year>
              <volume>34</volume>
              <fpage>1076</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
<italic toggle="yes">(31 year old man developed symptomatic kidney stones 8 days after starting iv ceftriaxone, resolving spontaneously).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">10981257</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.prince.2003.648">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Prince</surname><given-names>JS</given-names></name>
<name name-style="western"><surname>Senac</surname><given-names>MO</given-names><suffix>Jr</suffix></name>
</person-group>
              <article-title>Ceftriaxone-associated nephrolithiasis and biliary pseudolithiasis in a child.</article-title>
              <source>Pediatr Radiol</source>
              <year>2003</year>
              <volume>33</volume>
              <fpage>648</fpage>
              <lpage>51</lpage>
              <annotation>
                <p>
<italic toggle="yes">(14 year old boy developed nephrolithiasis with pain and hematuria and increased creatinine; both biliary and urinary sludge found, referred to as "toothpaste"; resolution in 3 weeks).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">12830336</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.ravisha.2004.73">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Ravisha</surname><given-names>MS</given-names></name>
<name name-style="western"><surname>Godambe</surname><given-names>SV</given-names></name>
</person-group>
              <article-title>Ceftriaxone induced cholestasis in a neonate: a case report.</article-title>
              <source>Indian J Med Sci</source>
              <year>2004</year>
              <volume>58</volume>
              <fpage>73</fpage>
              <lpage>4</lpage>
              <annotation>
                <p>
<italic toggle="yes">(17 day old male developed cholestasis after 7 days of iv ceftriaxone; sludge on ultrasound, bilirubin 2.6 mg/dL, ALT 98 U/L, Alk P 1194 U/L, resolution within 3-7 days).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">14993721</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.wen.2004.290">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Wen</surname><given-names>HH</given-names></name>
<name name-style="western"><surname>Huang</surname><given-names>YK</given-names></name>
<name name-style="western"><surname>Zheng</surname><given-names>GL</given-names></name>
</person-group>
              <article-title>Ceftriaxone-associated gallbladder pseudolithiasis: report of one case.</article-title>
              <source>Acta Paediatr Taiwan</source>
              <year>2004</year>
              <volume>45</volume>
              <fpage>290</fpage>
              <lpage>2</lpage>
              <annotation>
                <p>
<italic toggle="yes">(5 year old boy developed cholelithiasis 5 days after starting ceftriaxone, resolving after 1 month).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">15868813</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.acun.2004.368">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Acun</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Erdem</surname><given-names>LO</given-names></name>
<name name-style="western"><surname>Sogut</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Erdem</surname><given-names>CZ</given-names></name>
<name name-style="western"><surname>Tomac</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Gundogdu</surname><given-names>S</given-names></name>
</person-group>
              <article-title>Ceftriaxone-induced biliary pseudolithiasis and urinary bladder sludge.</article-title>
              <source>Pediatr Int.</source>
              <year>2004</year>
              <volume>46</volume>
              <issue>3</issue>
              <fpage>368</fpage>
              <lpage>70</lpage>
              <annotation>
                <p>
<italic toggle="yes">(5 year old girl developed biliary colic after 3 days of ceftriaxone; laboratory tests were normal, but ultrasound showed both gallbladder and urinary bladder sludge, resolving spontaneous within 12 days of stopping).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">15151561</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.acun.2004.25">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Acun</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Erdem</surname><given-names>LO</given-names></name>
<name name-style="western"><surname>S&#x000f6;&#x0011f;&#x000fc;t</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Erdem</surname><given-names>CZ</given-names></name>
<name name-style="western"><surname>Toma&#x000e7;</surname><given-names>N</given-names></name>
<name name-style="western"><surname>G&#x000fc;ndo&#x0011f;du</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Cavuldak</surname><given-names>S</given-names></name>
</person-group>
              <article-title>Gallbladder and urinary tract precipitations associated with ceftriaxone therapy in children: a prospective study.</article-title>
              <source>Ann Trop Paediatr.</source>
              <year>2004</year>
              <volume>24</volume>
              <fpage>25</fpage>
              <lpage>31</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Prospective ultrasound study of 36 children given iv ceftriaxone for up to 14 days; 5 [14%] developed gallbladder and one [3%] urinary bladder stones, most were symptomatic, all resolved spontaneously).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">15005963</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.avci.2004.1069">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Avci</surname><given-names>Z</given-names></name>
<name name-style="western"><surname>Koktener</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Uras</surname><given-names>N</given-names></name>
<etal/>
</person-group>
              <article-title>Nephrolithiasis associated with ceftriaxone therapy: a prospective study in 51 children.</article-title>
              <source>Arch Dis Child</source>
              <year>2004</year>
              <volume>89</volume>
              <fpage>1069</fpage>
              <lpage>72</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Prospective study of 51 children with various infections treated with ceftriaxone iv or im for 5-10 days; nephrolithiasis found by ultrasound in 4 children [8%], all asymptomatic, 3 resolved in follow up; no risk factors found).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">15499067</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.bor.2004.322">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Bor</surname><given-names>O</given-names></name>
<name name-style="western"><surname>Dinleyici</surname><given-names>EC</given-names></name>
<name name-style="western"><surname>Kebapci</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Aydogdu</surname><given-names>SD</given-names></name>
</person-group>
              <article-title>Ceftriaxone-associated biliary sludge and pseudocholelithiasis during childhood: a prospective study.</article-title>
              <source>Pediatr Int</source>
              <year>2004</year>
              <volume>46</volume>
              <fpage>322</fpage>
              <lpage>4</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Prospective study of 38 children receiving iv ceftriaxone; ultrasound at 10 days showed gallstones in 29% and sludge in 8%; one child had symptoms; resolution usually occurred within 1 month, but sometimes required 3).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">15151550</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.evliyaoglu.2005.92">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Evliyaoglu</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Kizartici</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Bademci</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Unal</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Keskil</surname><given-names>S</given-names></name>
</person-group>
              <article-title>Ceftriaxone-induced symptomatic pseudolithiasis mimicking ICP elevation.</article-title>
              <source>Zentralbl Neurochir</source>
              <year>2005</year>
              <volume>66</volume>
              <fpage>92</fpage>
              <lpage>4</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Patient developed pseudolithiasis after neurosurgery and iv ceftriaxone; made differential diagnosis difficult).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">15846537</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.ceran.2005.256">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Ceran</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Oztoprak</surname><given-names>I</given-names></name>
<name name-style="western"><surname>Cankorkmaz</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Gumu&#x000e7;</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Yildiz</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Koyluoglu</surname><given-names>G</given-names></name>
</person-group>
              <article-title>Ceftriaxone-associated biliary pseudolithiasis in paediatric surgical patients.</article-title>
              <source>Int J Antimicrob Agents</source>
              <year>2005</year>
              <volume>25</volume>
              <fpage>256</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Prospective ultrasound study of 50 children treated with ceftriaxone after surgery; 13 [26%] developed sludge or stones within 4-22 days; resolved within 3-63 days, no enzyme elevations, no risk factors found).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">15737522</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.bell.2005.363">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Bell</surname><given-names>MJ</given-names></name>
<name name-style="western"><surname>Stockwell</surname><given-names>DC</given-names></name>
<name name-style="western"><surname>Luban</surname><given-names>NL</given-names></name>
<name name-style="western"><surname>Shirey</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Shaak</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Ness</surname><given-names>PM</given-names></name>
<name name-style="western"><surname>Wong</surname><given-names>ECC</given-names></name>
</person-group>
              <article-title>Ceftriaxone-induced hemolytic anemia and hepatitis in an adolescent with hemoglobin SC disease.</article-title>
              <source>Pediatr Crit Care Med</source>
              <year>2005</year>
              <volume>6</volume>
              <fpage>363</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
<italic toggle="yes">(17 year old boy with sickle cell disease and severe hemolytic anemia given ceftriaxone developed progressive renal and hepatic failure and death; liver failure likely due to shock).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">15857541</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.bickford.2005.1389">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Bickford</surname><given-names>CL</given-names></name>
<name name-style="western"><surname>Spencer</surname><given-names>AP</given-names></name>
</person-group>
              <article-title>Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: case report and review of the literature.</article-title>
              <source>Pharmacotherapy</source>
              <year>2005</year>
              <volume>25</volume>
              <fpage>1389</fpage>
              <lpage>95</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Review of literature on ceftriaxone associated pseudolithiasis; case report of 53 year old man with chronic hepatitis C who developed jaundice after 7 days of iv ceftriaxone with little change in ALT or AST [bilirubin 5.8 mg/dL, ALT 41 U/L, Alk P 88 U/L], which resolved only once ceftriaxone was stopped, but role of sepsis could not be excluded).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">16185184</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.rivkin.2005.2006">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Rivkin</surname><given-names>AM</given-names></name>
</person-group>
              <article-title>Hepatocellular enzyme elevations in a patient receiving ceftriaxone.</article-title>
              <source>Am J Health Syst Pharm</source>
              <year>2005</year>
              <volume>62</volume>
              <fpage>2006</fpage>
              <lpage>10</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Case report and literature review; seriously ill 31 year old man in ICU had increase in ALT from 9 to 56 to 442 U/L, but normal Alk P and bilirubin and no symptoms after 7 days of ceftriaxone therapy, with resolution within 2 weeks of switching antibiotics).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">16174837</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.biner.2006.217">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Biner</surname><given-names>B</given-names></name>
<name name-style="western"><surname>Oner</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Celtik</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Bostancio&#x0011f;lu</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Tun&#x000e7;bilek</surname><given-names>N</given-names></name>
<name name-style="western"><surname>G&#x000fc;zel</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Karasaliho&#x0011f;lu</surname><given-names>S</given-names></name>
</person-group>
              <article-title>Ceftriaxone-associated biliary pseudolithiasis in children.</article-title>
              <source>J Clin Ultrasound</source>
              <year>2006</year>
              <volume>34</volume>
              <fpage>217</fpage>
              <lpage>222</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 156 children given iv ceftriaxone who were followed prospectively with serial abdominal ultrasounds, 27 [17%] developed biliary stones or sludge and 5 [3%] became symptomatic; resolving within 10-30 days of stopping; risk factors were older age and higher doses of ceftriaxone).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">16673364</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.araz.2007.285">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Araz</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Okan</surname><given-names>V</given-names></name>
<name name-style="western"><surname>Demirci</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Araz</surname><given-names>M</given-names></name>
</person-group>
              <article-title>Pseudolithiasis due to ceftriaxone treatment for meningitis in children: report of 8 cases.</article-title>
              <source>Tohoku J Exp Med</source>
              <year>2007</year>
              <volume>211</volume>
              <fpage>285</fpage>
              <lpage>90</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Case series of 8 children with ceftriaxone induced pseudolithiasis; all resolved within 30 days).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">17347554</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.chalasani.2008.1924">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Chalasani</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Fontana</surname><given-names>RJ</given-names></name>
<name name-style="western"><surname>Bonkovsky</surname><given-names>HL</given-names></name>
<name name-style="western"><surname>Watkins</surname><given-names>PB</given-names></name>
<name name-style="western"><surname>Davern</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Serrano</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Yang</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Rochon</surname><given-names>J</given-names></name>
<collab>Drug Induced Liver Injury Network (DILIN)</collab>
</person-group>
              <article-title>Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.</article-title>
              <source>Gastroenterology</source>
              <year>2008</year>
              <volume>135</volume>
              <fpage>1924</fpage>
              <lpage>34</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 300 cases of drug induced liver disease in the US collected between 2004 and 2008, one case was attributed to ceftriaxone alone [85 year old man developed cholestatic hepatitis 3 weeks after a four day course of intravenous ceftriaxone]).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">18955056</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.peker.2009.2669">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Peker</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Cagan</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Dogan</surname><given-names>M.</given-names></name>
</person-group>
              <article-title>Ceftriaxone-induced toxic hepatitis.</article-title>
              <source>World J Gastroenterol</source>
              <year>2009</year>
              <volume>15</volume>
              <fpage>2669</fpage>
              <lpage>71</lpage>
              <annotation>
                <p>
<italic toggle="yes">(12 year old boy developed fatigue after 3 days of ceftriaxone therapy followed by jaundice [bilirubin 4.2 mg/dL, ALT 871 U/L, Alk P 143 U/L, 8% eosinophils], resolving within 10 weeks of stopping).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">19496200</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.ferrajolo.2010.721">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Ferrajolo</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Capuano</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Verhamme</surname><given-names>KM</given-names></name>
<name name-style="western"><surname>Schuemie</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Rossi</surname><given-names>F</given-names></name>
<name name-style="western"><surname>Stricker</surname><given-names>BH</given-names></name>
<name name-style="western"><surname>Sturkenboom</surname><given-names>MC</given-names></name>
</person-group>
              <article-title>Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase.</article-title>
              <source>Br J Clin Pharmacol</source>
              <year>2010</year>
              <volume>70</volume>
              <fpage>721</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Worldwide pharmacovigilance database contained 9036 hepatic adverse drug reactions in children, 104 of which were attributed to ceftriaxone, ranking 10th in frequency and being the only cephalosporin listed).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">21039766</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.reuben.2010.2065">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Reuben</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Koch</surname><given-names>DG</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>WM</given-names></name>
<collab>Acute Liver Failure Study Group</collab>
</person-group>
              <article-title>Drug-induced acute liver failure: results of a U.S. multicenter, prospective study.</article-title>
              <source>Hepatology</source>
              <year>2010</year>
              <volume>52</volume>
              <fpage>2065</fpage>
              <lpage>76</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, one of which was attributed to cefepime, but none to ceftriaxone or other cephalosporins).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">20949552</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.kaur.2011.474">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Kaur</surname><given-names>I</given-names></name>
<name name-style="western"><surname>Singh</surname><given-names>J</given-names></name>
</person-group>
              <article-title>Cholestatic hepatitis with intravenous ceftriaxone.</article-title>
              <source>Indian J Pharmacol</source>
              <year>2011</year>
              <volume>43</volume>
              <fpage>474</fpage>
              <lpage>5</lpage>
              <annotation>
                <p>
<italic toggle="yes">(24 year old woman developed dark urine 24 hours after starting ceftriaxone and piroxicam and 3 days later was jaundiced [bilirubin 6.5 mg/dL, ALT 164 U/L, Alk P 580 U/L], resolving within 3 weeks of stopping both drugs).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">21845011</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.choi.2011.423">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Choi</surname><given-names>YY</given-names></name>
<name name-style="western"><surname>Jung</surname><given-names>YH</given-names></name>
<name name-style="western"><surname>Choi</surname><given-names>SM</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>CS</given-names></name>
<name name-style="western"><surname>Kim</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Hur</surname><given-names>KY</given-names></name>
</person-group>
              <article-title>Gallbladder pseudolithiasis caused by ceftriaxone in young adult.</article-title>
              <source>J Korean Surg Soc</source>
              <year>2011</year>
              <volume>81</volume>
              <fpage>423</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Two men, ages 21 and 22 years, developed gallstones found by CT scan 5 and 17 days after starting ceftriaxone without symptoms or laboratory abnormalities, resolving within 1 month of stopping).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">22200045</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.hanata.2012.2955">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Hanata</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Imamura</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Koyama</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Koizumi</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Tamura</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Ito</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Takeuch</surname><given-names>K.</given-names></name>
</person-group>
              <comment>[Case report; a case of biliary pseudolithiasis associated with ceftriaxone]</comment>
              <source>Nihon Naika Gakkai Zasshi</source>
              <year>2012</year>
              <volume>101</volume>
              <fpage>2955</fpage>
              <lpage>7</lpage>
              <comment>Japanese.</comment>
              <pub-id pub-id-type="pmid">23214106</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.bj_rnsson.2013.1419">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Bj&#x000f6;rnsson</surname><given-names>ES</given-names></name>
<name name-style="western"><surname>Bergmann</surname><given-names>OM</given-names></name>
<name name-style="western"><surname>Bj&#x000f6;rnsson</surname><given-names>HK</given-names></name>
<name name-style="western"><surname>Kvaran</surname><given-names>RB</given-names></name>
<name name-style="western"><surname>Olafsson</surname><given-names>S</given-names></name>
</person-group>
              <article-title>Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland.</article-title>
              <source>Gastroenterology</source>
              <year>2013</year>
              <volume>144</volume>
              <fpage>1419</fpage>
              <lpage>25</lpage>
              <annotation>
                <p>
<italic toggle="yes">(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, of which 2 were attributed to cephalosporins, one with jaundice to cephalexin and one with enzyme elevations only to ceftazidime).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">23419359</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.rodr_guez_rangel.2014.77">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Rodr&#x000ed;guez Rangel</surname><given-names>DA</given-names></name>
<name name-style="western"><surname>Pinilla Orejarena</surname><given-names>AP</given-names></name>
<name name-style="western"><surname>Bustacara Diaz</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Henao Garc&#x000ed;a</surname><given-names>L</given-names></name>
<name name-style="western"><surname>L&#x000f3;pez Cadena</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Montoya Camargo</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Moreno</surname><given-names>LA</given-names></name>
</person-group>
              <comment>[Gallstones in association with the use of ceftriaxone in children.]</comment>
              <source>An Pediatr (Barc)</source>
              <year>2014</year>
              <volume>80</volume>
              <fpage>77</fpage>
              <lpage>80</lpage>
              <comment>Spanish.</comment>
              <annotation>
                <p>
<italic toggle="yes">(Prospective study in 73 children receiving ceftriaxone, identified sludge or gallstones [4-14 mm in diameter] by ultrasound in 31 [43%], of whom 7 had symptoms, all resolving within 2 months of stopping, but one requiring surgery).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">23759541</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.zheng.2013.696">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Zheng</surname><given-names>FY</given-names></name>
<name name-style="western"><surname>Xing</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Lu</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Liu</surname><given-names>DM</given-names></name>
</person-group>
              <comment>[Ceftriaxone-associated biliary pseudolithiasis in a child with nephrotic syndrome]</comment>
              <source>Zhongguo Dang Dai Er Ke Za Zhi</source>
              <year>2013</year>
              <volume>15</volume>
              <fpage>696</fpage>
              <lpage>7</lpage>
              <comment>Chinese.</comment>
              <pub-id pub-id-type="pmid">23965889</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.tomoda.2013.1481">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Tomoda</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Ueki</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Saito</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Tatsukawa</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Nawa</surname><given-names>T</given-names></name>
<name name-style="western"><surname>Hamamoto</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Endo</surname><given-names>H</given-names></name>
<etal/>
</person-group>
              <comment>[A case of ceftriaxone-associated pseudolithiasis in an adult patient that disappeared after the discontinuation of ceftriaxone]</comment>
              <source>Nihon Shokakibyo Gakkai Zasshi</source>
              <year>2013</year>
              <volume>110</volume>
              <fpage>1481</fpage>
              <lpage>6</lpage>
              <comment>Japanese.</comment>
              <annotation>
                <p>
<italic toggle="yes">(47 year old woman found to have developed biliary stones and sludge on CT scan after 8 days of intravenous ceftriaxone, which disappeared within 6 days).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">23912008</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.von_martels.2013">
            <mixed-citation publication-type="other">von Martels JZ, Van de Meeberg EK, Holman M, Ligtenberg JJ, Ter Maaten JC. Pseudolithiasis after recent use of ceftriaxone: an unexpected diagnosis in a child with abdominal pain. Am J Emerg Med 2013; 31: 1294. e5-6.<annotation><p><italic toggle="yes">(14 year old boy treated for Lyme disease with a 2 week course of iv ceftriaxone presented 4 days later with abdominal pain and biliary stones by ultrasound and ERCP [bilirubin 4.2 mg/dL, ALT 187 U/L, Alk P 398, GGT 291 U/L], resolving with conservative management within a few days and no stones found on follow-up ultrasound 4 weeks later).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Ceftriaxone.REF.hern_ndez.2014.231">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Hern&#x000e1;ndez</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Bessone</surname><given-names>F</given-names></name>
<name name-style="western"><surname>S&#x000e1;nchez</surname><given-names>A</given-names></name>
<name name-style="western"><surname>di Pace</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Brahm</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Zapata</surname><given-names>R, A</given-names></name>
<name name-style="western"><surname>Chirino</surname><given-names>R</given-names></name>
<etal/>
</person-group>
              <article-title>Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports.</article-title>
              <source>Ann Hepatol</source>
              <year>2014</year>
              <volume>13</volume>
              <fpage>231</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, but none were attributed to ceftriaxone or a cephalosporin).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">24552865</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.alemayehu.2014.323">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Alemayehu</surname><given-names>H</given-names></name>
<name name-style="western"><surname>Desai</surname><given-names>AA</given-names></name>
<name name-style="western"><surname>Thomas</surname><given-names>P</given-names></name>
<name name-style="western"><surname>Sharp</surname><given-names>SW</given-names></name>
<name name-style="western"><surname>St Peter</surname><given-names>SD</given-names></name>
</person-group>
              <article-title>Ceftriaxone-induced pseudolithiasis in children treated for perforated appendicitis.</article-title>
              <source>Pediatr Surg Int</source>
              <year>2014</year>
              <volume>30</volume>
              <fpage>323</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 71 children treated with iv ceftriaxone for perforated appendicitis, 10 [14%] developed gallbladder stones or sludge, one of whom developed symptoms and underwent cholecystectomy).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">24464035</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.chalasani.2015.1340">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Chalasani</surname><given-names>N</given-names></name>
<name name-style="western"><surname>Bonkovsky</surname><given-names>HL</given-names></name>
<name name-style="western"><surname>Fontana</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>W</given-names></name>
<name name-style="western"><surname>Stolz</surname><given-names>A</given-names></name>
<name name-style="western"><surname>Talwalkar</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Reddy</surname><given-names>KR</given-names></name>
<etal/>
<collab>United States Drug Induced Liver Injury Network</collab>
</person-group>
              <article-title>Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study.</article-title>
              <source>Gastroenterology</source>
              <year>2015</year>
              <volume>148</volume>
              <fpage>1340</fpage>
              <lpage>52.e7</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 899 cases of drug induced liver injury seen over a ten year period at 8 U.S. medical centers, 323 [36%] were attributed to antibiotics of which 36 [4%] were cephalosporins including cefazolin [21], ceftriaxone [4], cefalexin [3], cefadroxil [2] and cefuroxime [2] and four others [1 case each]).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">25754159</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.alqahtani.2015.1328">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Alqahtani</surname><given-names>SA</given-names></name>
<name name-style="western"><surname>Kleiner</surname><given-names>DE</given-names></name>
<name name-style="western"><surname>Ghabril</surname><given-names>M</given-names></name>
<name name-style="western"><surname>Gu</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Hoofnagle</surname><given-names>JH</given-names></name>
<name name-style="western"><surname>Rockey</surname><given-names>DC</given-names></name>
<collab>Drug-Induced Liver Injury Network (DILIN) Study Investigators</collab>
</person-group>
              <article-title>Identification and characterization of cefazolin-induced liver injury.</article-title>
              <source>Clin Gastroenterol Hepatol</source>
              <year>2015</year>
              <volume>13</volume>
              <fpage>1328</fpage>
              <lpage>36.e2</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 1019 patients enrolled in a US database of drug induced liver injury between 2004 and 2012, 33 [3%] were due to cephalosporins, of which 19 presented 6-29 days after a single iv injection of cefazolin exhibiting a cholestatic pattern of injury, mild immunoallergic features, moderate severity and invariably a self-limited course).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">25528012</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.nakaharai.2016.1003">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Nakaharai</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Sakamoto</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Yaita</surname><given-names>K</given-names></name>
<name name-style="western"><surname>Yoshimura</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Igarashi</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Tachikawa</surname><given-names>N</given-names></name>
</person-group>
              <article-title>Drug-induced liver injury associated with high-dose ceftriaxone: a retrospective cohort study adjusted for the propensity score.</article-title>
              <source>Eur J Clin Pharmacol.</source>
              <year>2016</year>
              <volume>72</volume>
              <issue>8</issue>
              <fpage>1003</fpage>
              <lpage>11</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Retrospective analysis of 471 patients treated with ceftriaxone found that 15 [3.2%] developed abnormal liver tests within two weeks of treatment, including 16% receiving high dose [4 g daily] vs 2.1% receiving standard dose [2 g daily]).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">27126206</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.bonkovsky.2017.1267">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Bonkovsky</surname><given-names>HL</given-names></name>
<name name-style="western"><surname>Kleiner</surname><given-names>DE</given-names></name>
<name name-style="western"><surname>Gu</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Odin</surname><given-names>JA</given-names></name>
<name name-style="western"><surname>Russo</surname><given-names>MW</given-names></name>
<name name-style="western"><surname>Navarro</surname><given-names>VM</given-names></name>
<name name-style="western"><surname>Fontana</surname><given-names>RJ</given-names></name>
<etal/>
<collab>U.S. Drug Induced Liver Injury Network Investigators</collab>
</person-group>
              <article-title>Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements.</article-title>
              <source>Hepatology.</source>
              <year>2017</year>
              <volume>65</volume>
              <fpage>1267</fpage>
              <lpage>1277</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 26 patients with drug induced liver injury and bile duct loss on liver biopsy, most developed severe cholestatic hepatitis an evidence of chronic residual liver injury suggestive of varying degrees of vanishing bile duct syndrome, 1 case was attributed to oral cephalexin and one to parenteral cefazolin but none to ceftriaxone).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">27981596</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.zhao.2017.e8009">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name>
<name name-style="western"><surname>Bao</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Yu</surname><given-names>X</given-names></name>
<name name-style="western"><surname>Zhu</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Xu</surname><given-names>J</given-names></name>
<name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>
<name name-style="western"><surname>Yin</surname><given-names>M</given-names></name>
<etal/>
</person-group>
              <article-title>Acute vanishing bile duct syndrome after therapy with cephalosporin, metronidazole, and clotrimazole: A case report.</article-title>
              <source>Medicine (Baltimore)</source>
              <year>2017</year>
              <volume>96</volume>
              <elocation-id>e8009</elocation-id>
              <annotation>
                <p>
<italic toggle="yes">(27 year old woman was treated with &#x0201c;cephalosporin&#x0201d;, metronidazole and clotrimazole after removal of an intrauterine device and developed evidence of liver injury several weeks later [bilirubin 1.7 mg/dL, ALT 335 U/L, Alk P 655 U/L], with persistence of jaundice for several months and liver biopsy showing paucity of bile ducts, but ultimate resolution of jaundice but persistence of mild Alk P elevations).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">28885366</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.low.2020.142">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Low</surname><given-names>EXS</given-names></name>
<name name-style="western"><surname>Zheng</surname><given-names>Q</given-names></name>
<name name-style="western"><surname>Chan</surname><given-names>E</given-names></name>
<name name-style="western"><surname>Lim</surname><given-names>SG</given-names></name>
</person-group>
              <article-title>Drug induced liver injury: East versus West &#x02013; a systematic review and meta-analysis.</article-title>
              <source>Clin Mol Hepatol.</source>
              <year>2020</year>
              <volume>26</volume>
              <fpage>142</fpage>
              <lpage>154</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Analysis of literature on causes of drug induced liver injury found that the most common causes from Asian reports were antituberculosis drugs [25%], phenytoin [3.5%], and cephalosporins [3%] while causes from European and American reports were most commonly amoxicillin/clavulanate [11%], nimesulide [6%], and ibuprofen [6%]).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">31816676</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.park.2021.642">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Park</surname><given-names>JH</given-names></name>
<name name-style="western"><surname>Hong</surname><given-names>S</given-names></name>
<name name-style="western"><surname>Jun</surname><given-names>DW</given-names></name>
<name name-style="western"><surname>Yoon</surname><given-names>JH</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>KN</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>HL</given-names></name>
<name name-style="western"><surname>Lee</surname><given-names>OY</given-names></name>
<etal/>
</person-group>
              <article-title>Prevalence and clinical characteristics of antibiotics associated drug induced liver injury.</article-title>
              <source>Ann Transl Med.</source>
              <year>2021</year>
              <volume>9</volume>
              <fpage>642</fpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 166 patients seen at a single Korean medical center over a 12 month period [2017-18] for serum enzyme elevations, 113 were attributed to drugs, including 78 [64%] to antibiotics, most frequently flomoxef [a cephalomycin, n=24], cetrazole [9], ceftriaxone [6], vancomycin [5], piperacillin-tazobactam [5], and amoxicillin/clavulanate [4], all of whom recovered upon stopping; unclear whether any were symptomatic or jaundiced).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">33987340</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.ferrajolo.2017.305">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Ferrajolo</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Verhamme</surname><given-names>KM</given-names></name>
<name name-style="western"><surname>Trifir&#x000f2;</surname><given-names>G</given-names></name>
<name name-style="western"><surname>'t Jong</surname><given-names>GW</given-names></name>
<name name-style="western"><surname>Picelli</surname><given-names>G</given-names></name>
<name name-style="western"><surname>Giaquinto</surname><given-names>C</given-names></name>
<name name-style="western"><surname>Mazzaglia</surname><given-names>G</given-names></name>
<etal/>
</person-group>
              <article-title>Antibiotic-induced liver injury in paediatric outpatients: a case-control study in primary care databases.</article-title>
              <source>Drug Saf.</source>
              <year>2017</year>
              <volume>40</volume>
              <fpage>305</fpage>
              <lpage>315</lpage>
              <annotation>
                <p>
<italic toggle="yes">(Among 938 cases of drug-associated liver injury in children identified in Italian and Dutch databases [with 93,665 controls] between 2000 and 2008, 138 arose after recent use of antibiotics including 26 linked to cephalosporins; cefaclor [n=8], cefixime [8], ceftriaxone [3], ceftibuten [3], cefpodoxime [2] and cefuroxime [1], the highest risk odds ratio being for ceftriaxone [14.7] and cefixime [6.1]).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">28025733</pub-id>
            </element-citation>
          </ref>
          <ref id="Ceftriaxone.REF.khurram.2015.462165">
            <element-citation publication-type="journal">
              <person-group>
<name name-style="western"><surname>Khurram</surname><given-names>D</given-names></name>
<name name-style="western"><surname>Shamban</surname><given-names>L</given-names></name>
<name name-style="western"><surname>Kornas</surname><given-names>R</given-names></name>
<name name-style="western"><surname>Paul</surname><given-names>M</given-names></name>
</person-group>
              <article-title>Marked direct hyperbilirubinemia due to ceftriaxone in an adult with sickle cell disease.</article-title>
              <source>Case Rep Gastrointest Med.</source>
              <year>2015</year>
              <volume>2015</volume>
              <elocation-id>462165</elocation-id>
              <annotation>
                <p>
<italic toggle="yes">(32 year old African American man with sickle cell disease during admission for an acute crisis and ceftriaxone and azithromycin therapy for suspected pneumonitis, had rise in total bilirubin levels from 3.3 to a peak of 17 mg/dL, which fell to baseline on switching antibiotics and resolution of the acute crisis; no direct bilirubin levels provided but increase was likely due to hemolysis and sepsis).</italic>
</p>
              </annotation>
              <pub-id pub-id-type="pmid">26101675</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Ceftriaxone.OHTER_REFERENCE_LINKS">
        <title>OHTER REFERENCE LINKS</title>
        <list list-type="order">
          <list-item>
            <label>1</label>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=ceftriaxone/AE+AND+Human%5BMH%5D+AND+(jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI+OR+hepatitis,+toxic%5BMH%5D)">Recent References on Ceftriaxone: from PubMed.gov</ext-link>
</p>
          </list-item>
          <list-item>
            <label>2</label>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=ceftriaxone">Trials on Ceftriaxone: from ClinicalTrials.gov</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
